In addition, he envisions the immune system as the mother of all systems, and therefore opened the flow cytometry laboratory to help understand the role of patho-physiology in diseases. Dr. Ayass established an aptamer laboratory that allows the discovery of aptamers for diagnostic and therapeutic applications in the fields of coagulation, allergy, cancer, and COVID-19. During the pandemic, Ayass Laboratory, LLC became among the best COVID-19 testing centers in Texas with the ability to turn around results in less than 24 hours for about 10,000 samples per day. Sequencing of SARS-CoV-2 by a team of scientists that was led by Dr. Ayass resulted in the discovery of the first Delta and Omicron variants in the DFW area. Dr. Ayass leads a team of scientists in designing panels for next generation sequencing that can turn around results in about 24 hours. At that point, it was quick and easy to generate data; however, the interpretation was lagging. For this reason, Dr. Ayass opened the bioinformatics department where data mining, creating algorithms for data analysis, and reporting became a major goal for our genomics program.
In the world of cancer, the focus is not only in providing data to help in chemo and immune therapies but also to be able to predict metastasis, which plays a key role in cancer survival. This led to an investigation of spatial profiling and single cell sequencing, and looking more in depth into cancer stem cell profiling, which is a key player in treatment resistance along with its role in cancer metastasis and ultimately cancer survival. Dr. Ayass plays a key role in the research and development at Ayass Bioscience, LLC and Ayass Laboratory, LLC.